Avascular Necrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major avascular necrosis markets reached a value of US$ 465.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 763.3 Million by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.
The avascular necrosis market has been comprehensively analyzed in IMARC's new report titled "Avascular Necrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Avascular necrosis, also called osteonecrosis, refers to a painful condition that results from a lack of blood supply to the bone. This causes the bone tissue to die, affecting a person's ability to move. Avascular necrosis most commonly affects the hip but can damage any joint bone tissue, such as ankles, jaw, knees, upper arm (humerus), and shoulders. The most prominent symptom of this ailment includes intermittent pain that arises when pressure is applied to the affected bone or while lying down. Individuals suffering from the disease may also experience stiff joints, limited range of motion, limping (if the hips or knees are affected), difficulty climbing stairs, walking, or standing, etc. The diagnosis of avascular necrosis usually depends on the patient's medical history, clinical features, and physical examination. The healthcare provider may perform specific diagnostic procedures, such as X-rays, bone scans, magnetic resonance imaging (MRI), computerized tomography (CT) scan, etc., to detect the cause of underlying indications.
The increasing cases of bone injuries, including broken bones and dislocated hips that can damage nearby blood vessels and interrupt the blood supply, are primarily driving the avascular necrosis market. Apart from this, the rising prevalence of several associated risk factors, such as joint or bone trauma, prolonged use of steroids, excessive alcohol consumption, smoking, etc., is also augmenting the market growth. Furthermore, the widespread adoption of nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen and naproxen sodium, to ease pain and improve patient well-being is creating a positive outlook for the market. Besides this, the escalating utilization of the core decompression technique, which involves surgical drilling into the region of dead bone around the joint to reduce pressure, enhance blood flow, and prevent further joint destruction, is also bolstering the market growth. Moreover, numerous pharmaceutical companies are investing in research initiatives for the development of highly potent, easier-to-administer, and economically viable painkillers. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of bone marrow aspirate concentration therapy, in which stem cells from the bone marrow are inserted into the affected part to grow new bone and improve function scores, is expected to drive the avascular necrosis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the avascular necrosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for avascular necrosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the avascular necrosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the avascular necrosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the avascular necrosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current avascular necrosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the avascular necrosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the avascular necrosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the avascular necrosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of avascular necrosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of avascular necrosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of avascular necrosis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with avascular necrosis across the seven major markets?
What is the size of the avascular necrosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of avascular necrosis?
What will be the growth rate of patients across the seven major markets?
Avascular Necrosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for avascular necrosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the avascular necrosis market?
What are the key regulatory events related to the avascular necrosis market?
What is the structure of clinical trial landscape by status related to the avascular necrosis market?
What is the structure of clinical trial landscape by phase related to the avascular necrosis market?
What is the structure of clinical trial landscape by route of administration related to the avascular necrosis market?
The avascular necrosis market has been comprehensively analyzed in IMARC's new report titled "Avascular Necrosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Avascular necrosis, also called osteonecrosis, refers to a painful condition that results from a lack of blood supply to the bone. This causes the bone tissue to die, affecting a person's ability to move. Avascular necrosis most commonly affects the hip but can damage any joint bone tissue, such as ankles, jaw, knees, upper arm (humerus), and shoulders. The most prominent symptom of this ailment includes intermittent pain that arises when pressure is applied to the affected bone or while lying down. Individuals suffering from the disease may also experience stiff joints, limited range of motion, limping (if the hips or knees are affected), difficulty climbing stairs, walking, or standing, etc. The diagnosis of avascular necrosis usually depends on the patient's medical history, clinical features, and physical examination. The healthcare provider may perform specific diagnostic procedures, such as X-rays, bone scans, magnetic resonance imaging (MRI), computerized tomography (CT) scan, etc., to detect the cause of underlying indications.
The increasing cases of bone injuries, including broken bones and dislocated hips that can damage nearby blood vessels and interrupt the blood supply, are primarily driving the avascular necrosis market. Apart from this, the rising prevalence of several associated risk factors, such as joint or bone trauma, prolonged use of steroids, excessive alcohol consumption, smoking, etc., is also augmenting the market growth. Furthermore, the widespread adoption of nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen and naproxen sodium, to ease pain and improve patient well-being is creating a positive outlook for the market. Besides this, the escalating utilization of the core decompression technique, which involves surgical drilling into the region of dead bone around the joint to reduce pressure, enhance blood flow, and prevent further joint destruction, is also bolstering the market growth. Moreover, numerous pharmaceutical companies are investing in research initiatives for the development of highly potent, easier-to-administer, and economically viable painkillers. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of bone marrow aspirate concentration therapy, in which stem cells from the bone marrow are inserted into the affected part to grow new bone and improve function scores, is expected to drive the avascular necrosis market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the avascular necrosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for avascular necrosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the avascular necrosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the avascular necrosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the avascular necrosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current avascular necrosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the avascular necrosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the avascular necrosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the avascular necrosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of avascular necrosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of avascular necrosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of avascular necrosis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with avascular necrosis across the seven major markets?
What is the size of the avascular necrosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of avascular necrosis?
What will be the growth rate of patients across the seven major markets?
Avascular Necrosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for avascular necrosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the avascular necrosis market?
What are the key regulatory events related to the avascular necrosis market?
What is the structure of clinical trial landscape by status related to the avascular necrosis market?
What is the structure of clinical trial landscape by phase related to the avascular necrosis market?
What is the structure of clinical trial landscape by route of administration related to the avascular necrosis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AVASCULAR NECROSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 AVASCULAR NECROSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AVASCULAR NECROSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 AVASCULAR NECROSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 AVASCULAR NECROSIS - UNMET NEEDS
10 AVASCULAR NECROSIS - KEY ENDPOINTS OF TREATMENT
11 AVASCULAR NECROSIS - MARKETED PRODUCTS
11.1 List of Avascular Necrosis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 AVASCULAR NECROSIS - PIPELINE DRUGS
12.1 List of Avascular Necrosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. AVASCULAR NECROSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. AVASCULAR NECROSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 AVASCULAR NECROSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Avascular Necrosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Avascular Necrosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Avascular Necrosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Avascular Necrosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Avascular Necrosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Avascular Necrosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Avascular Necrosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Avascular Necrosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Avascular Necrosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Avascular Necrosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Avascular Necrosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Avascular Necrosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Avascular Necrosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Avascular Necrosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Avascular Necrosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Avascular Necrosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Avascular Necrosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Avascular Necrosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Avascular Necrosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Avascular Necrosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Avascular Necrosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Avascular Necrosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Avascular Necrosis - Access and Reimbursement Overview
16 AVASCULAR NECROSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 AVASCULAR NECROSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 AVASCULAR NECROSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AVASCULAR NECROSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 AVASCULAR NECROSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AVASCULAR NECROSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 AVASCULAR NECROSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 AVASCULAR NECROSIS - UNMET NEEDS
10 AVASCULAR NECROSIS - KEY ENDPOINTS OF TREATMENT
11 AVASCULAR NECROSIS - MARKETED PRODUCTS
11.1 List of Avascular Necrosis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 AVASCULAR NECROSIS - PIPELINE DRUGS
12.1 List of Avascular Necrosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. AVASCULAR NECROSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. AVASCULAR NECROSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 AVASCULAR NECROSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Avascular Necrosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Avascular Necrosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Avascular Necrosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Avascular Necrosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Avascular Necrosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Avascular Necrosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Avascular Necrosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Avascular Necrosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Avascular Necrosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Avascular Necrosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Avascular Necrosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Avascular Necrosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Avascular Necrosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Avascular Necrosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Avascular Necrosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Avascular Necrosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Avascular Necrosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Avascular Necrosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Avascular Necrosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Avascular Necrosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Avascular Necrosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Avascular Necrosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Avascular Necrosis - Access and Reimbursement Overview
16 AVASCULAR NECROSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 AVASCULAR NECROSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 AVASCULAR NECROSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
